Cost comparison of continued anticoagulation with rivaroxaban versus placebo based on the one-year EINSTEIN-Extension trial efficacy and safety results.

CONCLUSIONS: Total healthcare costs were estimated to be lower for patients continuing rivaroxaban therapy compared to those receiving placebo in VTE patients who had completed 6 to 12 months of VTE treatment. PMID: 29469638 [PubMed - as supplied by publisher]
Source: Journal of Medical Economics - Category: Health Management Tags: J Med Econ Source Type: research